SCHEMBL20239283

SCHEMBL20239283

CCc1nc(C#N)cc(Oc2ccc(CS(=O)(=O)N(C)C(=O)O)cc2)n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.34
MAPK8 P45983 2/20 0.33
MAPK9 P45984 1/20 0.33
RAB9A P51151 2/20 0.33
NPC1 O15118 1/20 0.33
GPR119 Q8TDV5 1/20 0.33
P2RX3 P56373 2/20 0.32
PTPN2 P17706 1/20 0.32
PTPN1 P18031 1/20 0.32
PTPN6 P29350 1/20 0.32
LMNA P02545 2/20 0.32
HTT P42858 1/20 0.32
ALDH1A1 P00352 2/20 0.31
SCN9A Q15858 2/20 0.31
MMP2 P08253 1/20 0.31
MMP9 P14780 1/20 0.31
PDE4B Q07343 1/20 0.31
CACNA1B Q00975 2/20 0.31
CACNA1H O95180 1/20 0.31
NR3C1 P04150 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239134 0.90 PTPN1 (0.33) SMN1; SMN2MAPK8MAPK9PTPN2PTPN1
SCHEMBL16738672 0.88 PDE2A (0.36) SMN1; SMN2MAPK8MAPK9RAB9ANPC1
SCHEMBL20252431 0.88 SMN1; SMN2 (0.32) SMN1; SMN2MAPK8MAPK9RAB9ANPC1
SCHEMBL20239280 0.86 SMN1; SMN2 (0.46) SMN1; SMN2RAB9ANPC1GPR119P2RX3
SCHEMBL20239142 0.86 ALDH1A1 (0.36) SMN1; SMN2MAPK8MAPK9P2RX3ALDH1A1
SCHEMBL20239238 0.85 KDM4E (0.35) SMN1; SMN2LMNAHTTALDH1A1SCN9A
SCHEMBL20239206 0.84 SMN1; SMN2 (0.37) SMN1; SMN2RAB9ANPC1PTPN2PTPN1
SCHEMBL20239258 0.83 PDE4B (0.34) SMN1; SMN2MAPK8MAPK9LMNAHTT
SCHEMBL20252433 0.78 MAPK8 (0.30) MAPK8MAPK9L3MBTL1
SCHEMBL18249872 0.76 SMN1; SMN2 (0.40) SMN1; SMN2RAB9AGPR119PTPN2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT SMN1; SMN2 4828/4885MAPK8 4063/4885MAPK9 1933/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT SMN1; SMN2 4835/4885MAPK8 4095/4885MAPK9 1909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.